1. Home
  2. HIO vs RIGL Comparison

HIO vs RIGL Comparison

Compare HIO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIO
  • RIGL
  • Stock Information
  • Founded
  • HIO 1993
  • RIGL 1996
  • Country
  • HIO United States
  • RIGL United States
  • Employees
  • HIO N/A
  • RIGL N/A
  • Industry
  • HIO Finance/Investors Services
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIO Finance
  • RIGL Health Care
  • Exchange
  • HIO Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • HIO 374.7M
  • RIGL 335.5M
  • IPO Year
  • HIO N/A
  • RIGL 2000
  • Fundamental
  • Price
  • HIO $3.94
  • RIGL $39.31
  • Analyst Decision
  • HIO
  • RIGL Buy
  • Analyst Count
  • HIO 0
  • RIGL 5
  • Target Price
  • HIO N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • HIO 305.3K
  • RIGL 950.5K
  • Earning Date
  • HIO 01-01-0001
  • RIGL 08-05-2025
  • Dividend Yield
  • HIO 10.33%
  • RIGL N/A
  • EPS Growth
  • HIO N/A
  • RIGL N/A
  • EPS
  • HIO N/A
  • RIGL 5.43
  • Revenue
  • HIO N/A
  • RIGL $267,921,000.00
  • Revenue This Year
  • HIO N/A
  • RIGL $59.93
  • Revenue Next Year
  • HIO N/A
  • RIGL N/A
  • P/E Ratio
  • HIO N/A
  • RIGL $7.23
  • Revenue Growth
  • HIO N/A
  • RIGL 105.62
  • 52 Week Low
  • HIO $3.52
  • RIGL $12.40
  • 52 Week High
  • HIO $4.03
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • HIO 45.71
  • RIGL 70.84
  • Support Level
  • HIO $3.90
  • RIGL $39.00
  • Resistance Level
  • HIO $3.97
  • RIGL $42.08
  • Average True Range (ATR)
  • HIO 0.02
  • RIGL 2.31
  • MACD
  • HIO -0.00
  • RIGL -0.13
  • Stochastic Oscillator
  • HIO 42.00
  • RIGL 61.21

About HIO Western Asset High Income Opportunity Fund Inc.

Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: